This year will see the end of one of the main funding routes for ACTs — the Affordable Medicines Facility — Malaria (AMFm) programme, run by the Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva, Switzerland. Its demise may not leave enough alternative funding to pay for the extra treatments made possible by the semi-synthetic process. Furthermore, if Sanofi’s product is rushed into pharmacies at similar prices to existing products, it could disrupt an already volatile market